Marfan Sartan: a randomized, double-blind, placebo-controlled trial

Abstract

Losartan was able to decrease blood pressure in patients with MFS but not to limit aortic dilatation during a 3-year period in patients >10 years old. β-Blocker therapy alone should therefore remain the standard first line therapy in these patients.